Bio-Techne Corporation (TECH) fair value analysis
S&P 500 & Nasdaq · Updated 2026-09-07
Bio-Techne Corporation is a life sciences company that develops and manufactures proteins, antibodies, and other reagents used in research and diagnostics. The company operates globally, serving customers in academic institutions, pharmaceutical and biotechnology companies, and clinical diagnostic laboratories across North America, Europe, and Asia.
Forward Fair Value verdict
UndervaluedBased on TickrTrends' weekly Forward Fair Value model, TECH is trading at a 10–25% discount to estimated fair value.
TECH currently ranks #49 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.
- Last price
- $72.43
- Sector
- Healthcare
- 12-month range
- $50.79–$72.18
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- A
- Leverage
- Low
- Margin trend
- Contracting
- Revenue growth
- Modest
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for TECH
- Our model validated 17 trailing price-to-earnings windows for TECH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $50.79–$72.18.
- The 14-day relative strength index sits at a neutral 60.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for TECH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent TECH news
TickrTrends' derived news-sentiment signal for TECH is currently mixed, computed from recent coverage.
- Is Wall Street Bullish or Bearish on Bio-Techne Stock? (finance.yahoo.com, 2026-08-18)
TickrTrends take: Wall Street sentiment toward Bio-Techne represents one data point that investors tracking TECH should weigh against the company's current undervalued status according to TickrTrends analysis. For valuation-focused readers, monitoring whether analyst sentiment shifts higher could either validate the current undervaluation thesis or suggest that market recognition of the company's value may be closing a gap. The Healthcare sector positioning of TECH means that shifts in Wall Street's bullish or bearish stance may reflect broader sector dynamics or company-specific developments that could pressure or support the current valuation disconnect.
What people are saying
Follow the TECH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for TECH in the Healthcare sector have undergone changes this week. The DCF cross-check band shifted from overvalued to none, while momentum moved from B to none. The current valuation verdict remains undervalued.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is TECH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), TECH is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is TECH's TickrTrends verdict?
TECH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does TECH compare to other Healthcare stocks?
TECH ranks #49 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is TECH overbought or oversold?
TECH's 14-day RSI is in neutral territory - neither overbought nor oversold.
More in Healthcare
Head-to-head comparisons
TECH vs BDX · TECH vs BTSG · TECH vs COLL · TECH vs EW · TECH vs EXEL